RedTouch PRO represents the next frontier in regenerative laser therapy, utilising an exclusive wavelength to achieve overall skin rejuvenation with no anaesthetic, no downtime and the ability to treat all skin types.

Distributed by High Tech Medical, RedTouch PRO by Deka is the world’s first and only collagen-targeting fractional laser. Its exclusive wavelength and unique mechanism of action work on the chromatic component of skin in the epidermis and on the collagen component at the dermal level, making it ideal for treating lines and wrinkles, dyschromia, melasma, skin laxity, skin rejuvenation and more. RedTouch PRO combines the laser energy with Deka’s skin cooling MOVEO system to deliver optimum treatment performance, speed, comfort and efficacy without causing damage to the epidermis – thereby minimising side effects and related downtime.

The advanced RedTouch PRO handpiece, equipped with an integrated scanner system, has been designed to achieve the ultimate performance in transmitting energy to the skin with optimised ergonomics, treating all skin types, including dark phototypes.

RedTouch PRO also offers the ReLive treatment, which acts as a preventative rejuvenation treatment with little to no downtime. The unique stimulative effect of the RedTouch PRO wavelength means the ReLive treatment visibly revitalises the skin and can be performed as an alternative or complementary treatment to injectables.

‘The success of High Tech Medical is largely due to launching game-changing technologies and selecting the right products to complement our portfolio – innovative products and treatments that will in some way change how practitioners can treat their patients, with the focus being less-invasive treatments and better results.

This is precisely what Deka has achieved with the new RedTouch PRO, which is the first and only fractional laser targeting collagen for overall skin regeneration,’ says Matt Moncrieff, Managing Director of High Tech Medical.

‘There is a growing demand from both practitioners and patients for minimally-invasive procedures that provide effective results without the inconvenience of downtime and side effects, along with treatments that provide a preventative action and can be used as an alternative or adjunct to injectables.

‘The RedTouch PRO delivers visible results in the treatment of multiple skin concerns on all skin types, including dark phototypes, and with no anaesthetic and minimal downtime, making it an attractive solution for clinics and their patients.

‘RedTouch PRO is a compelling option for clinics and practitioners seeking a new technology that will allow them to attract new patients and optimise clinical outcomes for signs of ageing and preventative skin ageing in a minimally invasive manner.’

‘THE REDTOUCH PRO DELIVERS VISIBLE RESULTS FOR MULTIPLE SKIN CONCERNS WITH NO ANAESTHETIC AND MINIMAL DOWNTIME, MAKING IT AN ATTRACTIVE SOLUTION FOR CLINICS AND THEIR PATIENTS.’ Matt Moncrief, Managing Director, High Tech Medical

A new wavelength system for a new type of rejuvenation

  • Unique and exclusive wavelength targeting collagen for overall skin regeneration
  • Powerful collagen stimulation
  • Proven to assist with the treatment of melasma
  • Minimal side effects, even in dark phototypes
  • ReLive treatment ideal for preventative skin rejuvenation
  • Fast ROI with no consumables
RedTouch Pro by Deka device

Q&A with Prof Paolo Bonan
Dermatologist, Florence, Italy

Prof_Paolo_Bonan

What are RedTouch PRO’s differentiating features?

The RedTouch PRO system is a 675nm laser for dermatological and aesthetic applications such as skin ageing, treatment of benign pigmented lesions and acne scars. This wavelength works directly with collagen fibres rather than targeting water present in the skin and has minimal interaction with the vascular component. In this way, the laser beam transfers heat directly to the collagen fibres, reducing the involvement with other chromophores.

Can you describe its unique mechanism of action?

The specific targeting of collagen and melanin combined with minimum interaction with both the vascular component and water present in the skin, makes this system very effective for the treatment of benign pigmented lesions and photoaged skin. It reduces the risk of side effects and simplifies post-treatment management.

RedTouch PRO can have different effects on the tissue. At low energies, it creates a reversible thermal area that biostimulates down to a depth of 3-5mm. Increasing the energy promotes the formation of a denaturation column down to a depth of 0.5-1mm and a deeper reversible heating.

This collagen fibre denaturation leads to a neo-collagenesis process that is reported in several published pre-clinical studies. For example, a study where the cell cultures of adult human fibroblasts are irradiated shows that this device modulates cell proliferation and collagen synthesis. These results were confirmed by histological studies showing a significant increase of thin and newly formed fibres in the treated area. Moreover, the skin specimen collected from the treated area showed more parallel and straighter reticular elastic fibres in the dermis.

In addition, another histological study shows homogeneous damage of the pigment component on the entire scan area in the pigmented tissue macroscopically attributable to a paradoxical blackening, typical of laser treatment of these lesions.

It is evident that the numerous possible combinations of the operating parameters of the RedTouch PRO allows one to obtain different effects and therefore to treat various aspects of photoageing.

What are the key benefits of a 675nm wavelength?

The main key benefit is the excellent selectivity of this wavelength; it targets collagen with low absorption of water in the skin or vascular components.

Unlike other wavelengths that interact with water, the 675nm laser allows all the energy delivered to be targeted directly on the collagen. Thus, it reduces the energy yet maintains the same effectiveness. Reducing the energy is very important to minimise possible side effects and patient discomfort. Moreover by using this wavelength, the selectivity to collagen is higher than the melanin selectivity so that patients with all phototypes can be treated.

All these features offer an effective, fast, comfortable and minimal- downtime treatment. In addition, it allows doctors to offer their patients a treatment that is reliable and effective for every phototype and with no need for excessive post- treatment care.

What is the patient experience like?

My patients have found RedTouch PRO treatments to be pain-free. Minimal discomfort may be experienced, usually rated with a score of 1-2 on the VAS scale (5 points: maximum pain). The downtime of rejuvenation treatments with RedTouch PRO is also minimal. The slight redness that is generated after a treatment typically disappears within a few hours. Pigmented lesions are expelled via exfoliation within 14-21 days after treatment.

The number of sessions depends on the type of treatment and the desired results but it can vary from 1 to 4 and with no specific post- treatment care required.

Anything else you wish to add?

RedTouch PRO is an ever-evolving device. The 675nm is a wavelength that acts on the collagen in the dermis, but it does so much more! It can act on the collagen in the walls of small capillaries, making it possible to reduce diffuse skin redness, as well as offer an effective solution in the treatment of melasma. AMP

‘THIS WAVELENGTH WORKS DIRECTLY WITH COLLAGEN FIBRES RATHER THAN TARGETING WATER PRESENT IN THE SKIN AND HAS MINIMAL INTERACTION WITH THE VASCULAR COMPONENT.’

BEFORE
AFTER RedTouch Pro treatment.
AFTER RedTouch Pro treatment. Courtesy of Prof. Paolo Bonan MD, Italy
BEFORE
AFTER RedTouch Pro treatment. Courtesy of Prof. Paolo Bonan MD, Italy
BEFORE
AFTER RedTouch Pro treatment. Courtesy of Prof. Paolo Bonan MD, Italy

RedTouch PRO is distributed by High Tech Medical. For more information call 1300 309 233, email info@hightechmedical.com.au or visit www.hightechmedical.com.au

Previous articleQ&A: the making of SkinCeuticals’ Cell Cycle Catalyst
Next articleGLP-1 drugs don’t raise pancreatic cancer risk